VectorY Therapeutics has appointed Jessica Atkinson as Chief Business Officer. In this newly created role, she will support the CEO and leadership team in shaping long-term commercial strategy and forging key partnerships.
Jessica brings over 20 years’ experience in business development and commercial strategy within biopharma. She has held leadership roles at ImmuneID, Glympse Bio and Foundation Medicine, where she drove corporate strategy and strategic partnerships.
She also spent seven years in the US commercial team at Merck & Co. Most recently, she advised multiple early-stage biotech companies through her consultancy, TwoStep Advisors.
CEO Jim Scibetta commented: “Her proven expertise in shaping strategy and driving successful transactions across all stages of drug development will be invaluable as we advance our pipeline and pursue new opportunities.”
Jessica added: “VectorY’s pioneering approach to developing vectorised antibody therapeutics holds immense promise for patients with neurodegenerative diseases. I look forward to working with the team to grow our strategy and build transformative alliances that support our mission and long-term success.”
